Amplitude Vascular Systems (AVS), a medical device company pioneering solutions to safely and effectively treat severely calcified arterial disease, today announced the opening of its new global headquarters at 180 Third Avenue in Waltham, Massachusetts. The state-of-the-art facility spans 37,811 square feet and will serve as the company’s central hub for innovation, operations, and commercialization. This expansion reflects AVS’s rapid growth and positions the company for its next phase: bringing its novel pulsatile intravascular lithotripsy (PIVL) therapy, the PULSE™ IVL System, to the U.S. market.
A Strategic Move to a Thriving Life Sciences Hub
The decision to establish the new headquarters in Waltham underscores AVS’s commitment to long-term growth and access to top talent.
“Waltham and the Greater Boston region are among the most vibrant innovation ecosystems in the country,” said Mark Toland, Chairman of the Board at AVS. “This area provides unparalleled opportunities to recruit the best and brightest in medical technology. As we continue to build momentum toward regulatory approval in the U.S., our new space gives us the infrastructure to scale and to deliver the next generation of intravascular lithotripsy therapy for patients with peripheral and coronary artery disease.”
City officials also welcomed the company’s expansion. Mayor McCarthy of Waltham remarked, “AVS is joining a thriving hub for cutting-edge life sciences companies here in Waltham, and we are proud to welcome them to the city. The company’s growth and upcoming milestones will create quality jobs for our community, and we look forward to their continued success.”
A Facility Designed for Innovation and Growth
The headquarters at 180 Third Avenue was completed in 2023 as part of a modern, multi-tenant development. The location offers easy access to public transit, major highways, and Logan International Airport, making it well-positioned to support AVS’s growing global footprint.
Inside, the new facility houses:
- Research and development labs equipped for advanced product development.
- Manufacturing spaces to support both clinical and future commercial-scale production.
- Flexible office and meeting areas to accommodate the company’s expanding workforce and collaborative culture.
The combination of dedicated R&D and operations areas with administrative and general-use space will allow AVS to integrate its innovation pipeline with operational execution, a key factor as the company moves closer to commercialization.
Building on Momentum and Milestones
The move to Waltham caps a period of remarkable progress for AVS since the establishment of its original headquarters in Boston’s Seaport District in 2023. Among the company’s significant achievements are:
- June 2024 – Obtained Investigational Device Exemption (IDE) approval from the FDA to initiate the POWER PAD II pivotal study in the United States, evaluating the use of PIVL in femoropopliteal arteries.
- October 2024 – Commenced enrollment in the POWER PAD II study, which is anticipated to complete in 2025. The trial’s primary endpoints are scheduled to be presented as a Late Breaking Clinical Trial at the Vascular InterVentional Advances (VIVA) Conference in November 2025.
- January 2025 – Successfully closed a $36 million Series B financing round, which has fueled both the POWER PAD II trial for peripheral artery disease and the continued development of a coronary platform as well as other indication expansion opportunities.
These milestones highlight AVS’s rapid trajectory as it advances its PULSE™ IVL System toward regulatory review and eventual market launch.
Preparing for Commercialization
AVS leaders emphasized that the new headquarters is more than a physical expansion — it is a strategic investment in the company’s future.
“The new headquarters is a testament to our progress as we grow our team and prepare to bring our innovative solution for calcified arterial disease to market,” said Sean Gilligan, Chief Operating Officer at AVS. “Our dedicated R&D and operations spaces have already accelerated our technical capabilities and strengthened our manufacturing strategy. These advancements will be critical as we prepare for the anticipated commercialization of our first platform in mid-2026.”
The PULSE™ IVL System, designed to safely fracture vascular calcium using pulsatile intravascular lithotripsy, represents a next-generation approach to treating severely calcified lesions. By enabling improved vessel preparation in both peripheral and coronary arteries, the technology aims to expand treatment options for patients and provide physicians with a safe, effective alternative to existing therapies.
Looking Ahead
As AVS transitions from a clinical-stage company to a commercial-stage enterprise, its new headquarters in Waltham provides the infrastructure and resources needed to support this evolution. The expansion quadruples the company’s operational capacity and positions AVS to scale manufacturing, expand clinical programs, and execute on its commercialization strategy.
The opening of the new headquarters also signals AVS’s long-term commitment to the Boston life sciences cluster, where access to a world-class talent pool, proximity to leading academic and medical institutions, and a supportive innovation ecosystem will continue to fuel its growth.
With the PULSE™ IVL System advancing through pivotal clinical evaluation and commercialization targeted for mid-2026, AVS is poised to make a significant impact in the treatment of calcified arterial disease — a critical area of unmet medical need.
To learn more about AVS and the PULSE IVL System, please visit https://www.avspulse.com.
About AVS
Amplitude Vascular Systems (AVS) is a medical device company based in Boston, MA, focused on safely and effectively treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital, Cue Growth Partners, and others. To learn more about pulsatile intravascular lithotripsy, visit www.avspulse.com.The Pulse Peripheral Intravascular Lithotripsy (IVL) System is an investigational device and not yet cleared for commercial distribution within or outside the United States.
